In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Konstantin Krychtiuk (Austria) - Winner YIA 2012

Testimonial

Acute Coronary Syndromes (ACS)


Curriculum Vitae:
October 2001 - On going: PhD student in vascular biology, Medical University of Vienna
August 2008  - ongoing: Research fellow at the Department of Internal Medicine II - Division of Cardiology; main field of research: ischemia-reperfusion injury, SIRS, inflammatory processes in atherosclerosis
2005 - 2011: Study of medicine, Medical University of Vienna
2004 - ongoing: paramedic & lecturer at St. John's Ambulance Vienna 

Abstract subject:

Inhibition of pro-inflammatory effects in human cardiac myocytes and endothelial cells by levosimendan

How did you come to this topic? 

In clinical trials it was shown that levosimendan is particularly effective in patients suffering from acute decompensated heart failure due to myocardial infarction. We hypothesized that levosimendan might exhibit anti-inflammatory effects on human cardiac myocytes and endothelial cells and by that dampen the myocardial reperfusion injury.

Abstract summary:

We hypothesized that levosimendan exhibits its beneficial effects during myocardial infarction and reperfusion injury by dampening the inflammatory response. Therefore, we induced inflammation in human cardiac myocytes and endothelial cells by adding inflammatory agents (TNF-α and IL-1b) and co-treated some of the cells with different concentrations of levosimendan (0.1 - 10 µM). Co-treatment with levosimendan lead to a marked reduction of IL-6 and IL-8 production by myocytes, down-regulation of adhesion molecules and attenuation of granulocyte adherence in endothelial cells.

What this nomination/price could bring to your carreer?

This award by the acute cardiac care association lead to further recognition of my work by peers and seniors at my institution. This may be of help for finding a residency position for cardiology at a competitive department. On a personal level, it encouraged me to keep my enthusiasm for the basic and clinical research I am currently conducting.

Tell us how being a ACCA member  help you in your day to day work, in your future plan ?

For me, participation in this young ESC association may enhance international exchange with both seniors in this exciting field and peers that stand at the beginning of their career in cardiology and acute cardiac care like me. Exchange may include scientific exchange in the form of abstracts, poster or oral presentations at the annual conference, publication in the journal and the possibility of clinical exchange. Guidelines and position papers on hot or controversial topics in acute cardiac care may help and guide young cardiologists in their daily clinical practice.